01/20/2006 08:50 FAX 7606033820

## RECEIVED CENTRAL FAX CENTER

JAN 2 0 2006

PTC/SE/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Par	perwork Reduction Act of 1995	. no person	s are required to respond to a c Application Number			unless it	displays a valid OMB control number.	
				<del></del>	10/757,298			
TRANSMITTAL			Filing Date		1/14/2004			
FORM			First Named Inventor		Robert S. Andrews			
			Art Unit	1635				
(to be used for all correspondence after initial filing)			Examiner Name	Tracy Ann	Tracy Ann Viviemore			
Total Number of Peges in This Submission 8			Attorney Docket Number	ISIS0038-	ISIS0038-100 (CHEM0001US)			
ENCLOSURES (Check all that apply)    The After Allowance Communication to TC								
	smittal Form		Drawing(s) Licensing-related Papers				I Communication to Board eats and interferences	
	ter Final		Illion to Convert to a  ovisional Application wer of Attorney, Revocation			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter		
Extension	fildavits/declaration(s) i of Time Request Abandonment Request		Change of Correspondence Terminal Disclaimer Request for Refund	Address			Enclosure(s) (please identify	
	on Disclosure Statement		CD, Number of CD(s) Landscape Table on (	CD				
Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53								
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
Firm Name Isis Pharmaceuticals, Inc.								
Signature	ignature Robert S. Onnews							
Printed name Robert S. Andrews								
Date	1-20-06 Reg				eg. No. 44,508			
CERTIFICATE OF TRANSMISSION/MAILING								
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:								
Signature VALULEUS								
	Laura Fames					Date	1/20/00	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or auggestions for reducing this burden, should be sent to the Chief information Officer. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**2**1002/008

Attorney Docket No: ISIS0038-100/CHEM0001US

Serial No. 10/757,298

January 20, 2006 Response to September 23, 2005 Action

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

In re application of: Andrews et al.

Group Art Unit:

<del>- JAN 2 0</del> 2006

Examiner:

Tracy Ann Vivlemore

Serial No.:

10/757,298

Confirmation No.:

5625

1635

Filed:

Jan. 14, 2004

Docket No.:

ISIS0038-100

(CHEM0001US)

For:

MODIFIED OLIGONUCLEOTIDES FOR USE IN GENE

**MODULATION** 

Certificate of Facsimile Transmission
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office to facsimile number 571-293-8300 on: 1/20/30

Mail Stop: Amendment

**Commissioner for Patents** 

P.O. Box 1450

Alexandria, VA 22313-1450

## AMENDMENT AND REQUEST FOR RECONSIDERATION UNDER 37 CFR § 1.111

In response to the Office Action mailed on September 23, 2005, please amend the above-identified application as follows:

Listing of Claims, reflecting current amendments, begins on page 2 of this paper.

Remarks begin on page 5 of this paper.